Open Label Study of Long Term Safety Evaluation of Alirocumab
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 986 participants.
Also called NCT01954394
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 986 participants
- Sponsor
- Registry
-
NCT01954394 -
2013-002572-40
-
- Other papers using this trial's data
- Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia
- Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Norway, Portugal, Romania, Russia, South Africa, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01954394. Allocation not applicable; no masking; primary purpose treatment. Start 2013-12-17 (registry gives no type); primary completion 2017-06-30 (actual). Results posted on 2018-07-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open Label Study of Long Term Safety Evaluation of Alirocumab
- Acronym
- ODYSSEY OLE
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Lipid-Modifying Therapy (LMT)
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct01954394- Content hash
80723e09063fd1874a71a71b0d11caace88446c2d36fe6f6f01caf752d204388